Murine gene fomy030 coding for tumor progression inhibitor
AssigneeMillennium Pharmaceuticals, Inc.
InventorAndrew W. Shyjan
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions for the diagnosis, prevention and treatment of tumor progression. Novel nucleic acid molecules are identified that are expressed at higher levels in benign (e.g., non-malignant) tumor cells compared to malignant tumor cells exhibiting a high metastatic potential. The nucleic acids and cells including these nucleic acids can be used diagnostically or for therapeutic intervention.
Claims12
An isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO:2, as depicted in FIG. 3.
An isolated nucleic acid which encodes the amino acid sequence of SDQ ID NO:3, as depicted in FIG. 3, from amino acid residue number 1 to 542, or its complement.
An isolated nucleic acid which hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:2 or its complement, wherein said isolated nucleic acid encodes a polypeptide that inhibits tumor progression or metastatic disease.
An isolated nucleic acid comprising the nucleotide sequence encoding the fomy030 gene contained in NRRL Deposit No. B-21416.
An isolated nucleic acid that hybridizes under stringent conditions to the nucleotide sequence encoding the fomy030 gene contained in NRRL Deposit No. B-21416, wherein said isolated nucleic acid encodes a polypeptide that inhibits tumor progression or metastatic disease.
Dependencies are inferred from the claim text.